Spotlight of the month: Mathys & Squire teams recommended in The Legal 500 2025 directory for their “unparalleled knowledge and experience in all areas of intellectual property”
Two CRISPR patents pulled from EPO appeals citing procedural concerns
EPO Board of Appeal finds no basis in EPC for requiring description amendments, and opts not to refer questions to the Enlarged Board
Emerging therapeutics and technology provide hope for menopause management
Semiconductor patent applications up 22% globally to 81,000 a year
Spotlight of the month: Unified Patent Court captures 15% of European patent litigation but still far from being primary European patent court
Changes to the proposed new medicinal products Directive have been approved by the EU Parliament – do they shift the balance between generics and innovators and are they TRIPS compliant?
Mathys & Squire files Petition for Review for Ipsen Bioinnovation
Mathys & Squire recognised as one of Europe’s leading patent firms in the Financial Times 2024 rankings
Fifteen Mathys & Squire attorneys recognised in IAM Patent 1000 2024